JeffreyArnoldMoscowMD

Summary

• Dr. Jeffrey Moscow graduated from Harvard University in 1973 and the Geisel School of Medicine at Dartmouth in 1982, and completed his training with a pediatrics internship and residency at the University of Texas Southwestern Medical Center and a fellowship in pediatric oncology at the National Cancer Institute (NCI) in the National Institutes of Health (NIH) Clinical Center. After fellowship, he continued basic and clinical research at NCI and joined the US Public Health Service. In 1997, he moved from NCI to the University of Kentucky, where he was Children’s Miracle Network Professor of Pediatrics, Chief of Pediatric Hematology-Oncology, Vice Chair of Pediatrics, and co-leader of the Experimental Therapeutics Program of the Markey Cancer Center. He returned to NCI in 2014 as a medical officer in the Investigational Drug Branch (IDB) of the Cancer Therapy Evaluation Program. He became branch chief of IDB in January, 2018 and retired in August, 2023. At NCI, Dr. Moscow also served as the initial program director of PDXNet, a grant program designed to incorporate pre-clinical evidence developed with patient-derived models into NCI’s clinical drug development efforts; and as the NCI co-lead of the ComboMATCH Precision Medicine Initiative, a clinical trial platform testing promising targeted drug combinations in multiple clinical trials. His scholarly work has included basic research into mechanisms of cancer drug resistance, and reports of early phase cancer clinical trials. He is an author of over 125 peer-reviewed publications, review articles and book chapters, and has been awarded 5 patents.